ClinicalTrials.gg
RecruitingNCT05072041Updated Nov 14, 2024

Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

An interventional study of Nexsphere™ in Hepatocellular Carcinoma, sponsored by Next Biomedical Co., Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Next Biomedical Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of — 50 open to participants now, 74 under way, 8 of them phase 3. Carcinoma, Hepatocellular · Korea, Republic of.

Planned enrollment
84th of 255
150 · median 87
Started
2021
with 18 others
No phase
59 of 298
9 open now
Primary completion
2025-08
later than 14 of 73 live
Registered
210th of 298
by date

Among the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, this one is the 84th largest by planned enrollment of the 255 interventional ones that give a count, is one of 19 that started in 2021, is one of 59 with no phase, reaches primary completion later than 14 of the 73 other live ones, and was the 210th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

50 of the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard treatment.

Read the detailed description

This study is a prospective study, and the purpose of this study is to investigate and collect clinical information on the safety and efficacy of degradable microsphere for hepatic artery chemoembolization in hepatocellular carcinoma patients. The primary purpose of this study was to evaluate the incidence of postembolism syndrome and liver function impairment after hepatic artery chemoembolization, and the secondary purpose was to evaluate tumor treatment response and hepatic artery damage after 1 month of hepatic artery chemoembolization.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients aged 19 to 79 years
  2. Patient who signed Form
  3. Patients diagnosed with hepatocellular carcinoma by American Association for the Study of Liver Diseases (AASLD) and at least one of the following methods i. Magnetic resonance imaging (MRI) with early augmentation and delayed excretion of at least one solid liver lesion greater than 1 ㎝.

    ii. Contrast-enhanced computed tomography (CT) with early augmentation and delayed build-up of at least one solid liver lesion >1 ㎝.

    iii. Lesions with inconclusive features require histological confirmation.

  4. Patients should not be eligible for treatment by amputation or percutaneous resection or liver transplantation at the time of study enrollment.

    i. Patients who are not suitable for ablation due to lesion location may be enrolled.

    ii. Patients with recurrent hepatocellular carcinoma who are not suitable for amputation or resection may be enrolled.

  5. Must be A or B hepatocellular carcinoma, and must satisfy the following criteria.

    i. Tumor lesion size from 1 ㎝ to 10 ㎝ ii. Number of tumors 1-7 iii. Physical activity European Cooperative Oncology Group () ≤ 1 without vascular involvement

  6. Patients who can be followed up until the end of the study and whose is 6 months or longer

Exclusion criteria

Exclusion Criteria:

  1. Patients under the age of 19
  2. Chronic kidney disease (CDK) grade 4 or 5 patients
  3. Current or previous treatment with chemotherapy or radiation therapy or sorafenib or drug release chemoembolization (deTACE) after diagnosis of hepatocellular carcinoma
  1. Pregnant, lactating, pre-menopausal and women not using effective methods 6. Performance state European Cooperative Oncology Group () > 1 7. Child-Poo Class C 8. Advanced hepatocellular carcinoma with vascular invasion or extrahepatic 9. Active Gastrointestinal Bleeding 10. Evidence of irreversible bleeding constitution 11. Encephalopathy that is not medically adequately controlled 12. Presence of ascites that is not medically controlled 13. to Magnetic Resonance Imaging or Computed Tomography scan (e.g. metal implants) 14. Allergy to contrast media that cannot be managed by prevention 15. Contraindications to angiography 16. Contraindications to the administration of cisplatin anticancer drugs 17. Contraindications to hepatic artery embolization
  • Extensive context-to-systemic shunts
  • hepatofugal portal blood flow
  • Serum > 3.0 ㎎/dL
  • Serum creatinine > 2.0 ㎎/dL
  • Other symptoms that your doctor has determined to be exclusive.
  • Irreversible blood clotting disorders 18. Others who are judged to be difficult for the principal investigator or principal investigator to conduct this clinical trial for other reasons
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Test group

    Degradable embolic microsphere (Nexsphere™)

    Device: Nexsphere™

Interventions

  • DeviceNexsphere™

    Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.

06

What researchers measure

Primary outcomes

  1. Incidence of postembolism syndrome

    Nausea, vomiting, persistent pain, fever, and other

    Time frame: 8 weeks

  2. Incidence of liver function impairment

    AFP, AST, ALT, BILI, GGT, BUN, and CREAT level

    Time frame: 8 weeks

Secondary outcomes

  1. Tumor treatment response

    Evaluation of tumor size by Magnetic Resonance Imaging or Computed Tomography scan at 4 and 8 weeks after embolization

    Time frame: 8 weeks

  2. Hepatic artery damage

    Vessel dissection, vessel stenosis, vessel occlusion, vessel wall irregularity, and other

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Aug 2025, 46 months after the start.

Of 385 interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 75. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 8, 2021
StartActual
Oct 31, 2021
Primary completionEst.
Aug 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05072041
Lead sponsor
Next Biomedical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 8, 2021
Start date
Oct 31, 2021
Primary completion
Aug 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 14, 2024

Study contacts

Jin Hee Maeng, MS
Contact
jhmaeng@nextbiomedical.co.kr
+8228800860
Dong Il Gwon, MD, PhD
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion